SCHEMBL6469267

SCHEMBL6469267

COc1ccc2nc(Nc3nc(OC(=O)C(F)(F)F)c4cc(N)ccc4n3)nc(C)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 1/20 0.46
KDM4E B2RXH2 10/20 0.46
ALDH1A1 P00352 11/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
LMNA P02545 3/20 0.43
RAB9A P51151 2/20 0.43
USP2 O75604 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MAPT P10636 9/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HTT P42858 2/20 0.43
HPGD P15428 3/20 0.42
ALOX12 P18054 2/20 0.42
NPC1 O15118 1/20 0.42
HIF1A Q16665 1/20 0.42
TSHR P16473 1/20 0.41
HSD17B10 Q99714 2/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6470555 0.90 KDM4E (0.44) TDP2KDM4EALDH1A1L3MBTL1MEN1
SCHEMBL6467461 0.89 KDM4E (0.44) TDP2KDM4EALDH1A1L3MBTL1MEN1
SCHEMBL6465739 0.86 ALDH1A1 (0.45) TDP2KDM4EALDH1A1L3MBTL1MEN1
SCHEMBL6468001 0.86 MAPT (0.45) TDP2KDM4EALDH1A1L3MBTL1MEN1
Trifluoroacetic Acid SCHEMBL6469262 0.84 TDP2 (0.48) TDP2KDM4EALDH1A1L3MBTL1MEN1
SCHEMBL6468616 0.83 TDP2 (0.43) TDP2KDM4EALDH1A1L3MBTL1MEN1
SCHEMBL6470389 0.83 TDP2 (0.43) TDP2KDM4EALDH1A1L3MBTL1MEN1
SCHEMBL6467060 0.83 TDP2 (0.43) TDP2KDM4EALDH1A1L3MBTL1MEN1
SCHEMBL6470164 0.82 TDP2 (0.41) TDP2KDM4EALDH1A1L3MBTL1MEN1
SCHEMBL6470579 0.82 TDP2 (0.44) TDP2KDM4EALDH1A1L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB TDP2 424/4885KDM4E 3225/4885ALDH1A1 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.